Ribo Life Science Enters Exclusive Licensing Agreement with Madrigal Pharmaceuticals
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Should l Buy MDGL?
Source: PRnewswire
- Exclusive Licensing Agreement: Ribo Life Science has entered into a global exclusive licensing agreement with Madrigal Pharmaceuticals for six pre-clinical small interfering RNA (siRNA) programs targeting metabolic dysfunction-associated steatohepatitis (MASH), which is expected to drive the development of new therapies to meet growing market demand.
- Financial Gains: Under the agreement, Ribo will receive an upfront payment of $60 million, with cumulative payments potentially reaching $4.4 billion upon achieving specific development, regulatory, and commercial milestones, highlighting the economic value and market potential of this collaboration.
- Technological Platform Advantage: The collaboration will leverage Ribo's GalSTARTM platform to develop bi-specific siRNAs, aiming to expand the therapeutic landscape for MASH through complementary multi-mechanistic approaches, thereby enhancing treatment efficacy and addressing unmet medical needs for patients.
- Growing Market Demand: As awareness of MASH disease increases and prevalence rises, the number of patients with moderate to advanced fibrosis is expected to grow, further driving the demand for new therapies and underscoring the significance of this collaboration.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MDGL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MDGL
Wall Street analysts forecast MDGL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDGL is 636.22 USD with a low forecast of 527.00 USD and a high forecast of 900.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 488.260
Low
527.00
Averages
636.22
High
900.00
Current: 488.260
Low
527.00
Averages
636.22
High
900.00
About MDGL
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Madrigal Pharmaceuticals Expands MASH Pipeline with New siRNA Programs
- Pipeline Expansion: Madrigal Pharmaceuticals has announced an exclusive global licensing agreement with Suzhou Ribo Life Science Co., acquiring six preclinical small interfering RNA (siRNA) programs, which is expected to enhance its leadership position in the metabolic dysfunction-associated steatohepatitis (MASH) space.
- Innovative Treatment Strategy: The company plans to develop next-generation siRNA therapies that target genes implicated in MASH, thereby precisely reducing the production of disease-driving proteins, which will provide more effective treatment options for patients with unmet medical needs.
- Clinical Research Progress: Currently, Madrigal's Rezdiffra is undergoing a fully enrolled F4c outcomes study, and its MASH pipeline has expanded to over 10 programs, including new drugs like MGL-2086 and Ervogastat, showcasing the company's robust R&D capabilities.
- Market Potential: With the increasing number of MASH patients, Madrigal's siRNA programs could potentially yield cumulative payments of up to $4.4 billion, indicating significant commercial potential in the rapidly growing MASH market.
See More
Madrigal Pharmaceuticals Enters $4.46B Licensing Deal with Suzhou Ribo
- Deal Value: Madrigal Pharmaceuticals has entered into an exclusive licensing agreement with Suzhou Ribo Life Science worth up to $4.46 billion, representing a significant advancement in the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
- Upfront Investment and Potential Earnings: Under the terms, Madrigal will pay Ribo $60 million upfront, with additional payments of up to $4.4 billion contingent on achieving development, regulatory, and commercial milestones, reflecting strong confidence in the collaboration.
- Technology Platform Utilization: Madrigal will leverage Ribo's liver-targeting small-interfering RNA (siRNA) GalSTAR platform to advance six preclinical programs aimed at developing new therapies for MASH, thereby enhancing treatment efficacy and addressing patient needs.
- Future Collaboration Expansion: The agreement includes provisions to expand the collaboration to new siRNA programs, such as bispecific siRNAs, indicating a long-term strategic partnership focused on innovative treatment solutions.
See More
Ribo Life Science Enters Exclusive Licensing Agreement with Madrigal Pharmaceuticals
- Exclusive Licensing Agreement: Ribo Life Science has entered into a global exclusive licensing agreement with Madrigal Pharmaceuticals for six pre-clinical small interfering RNA (siRNA) programs targeting metabolic dysfunction-associated steatohepatitis (MASH), which is expected to drive the development of new therapies to meet growing market demand.
- Financial Gains: Under the agreement, Ribo will receive an upfront payment of $60 million, with cumulative payments potentially reaching $4.4 billion upon achieving specific development, regulatory, and commercial milestones, highlighting the economic value and market potential of this collaboration.
- Technological Platform Advantage: The collaboration will leverage Ribo's GalSTARTM platform to develop bi-specific siRNAs, aiming to expand the therapeutic landscape for MASH through complementary multi-mechanistic approaches, thereby enhancing treatment efficacy and addressing unmet medical needs for patients.
- Growing Market Demand: As awareness of MASH disease increases and prevalence rises, the number of patients with moderate to advanced fibrosis is expected to grow, further driving the demand for new therapies and underscoring the significance of this collaboration.
See More
Ribo Life Science Enters Exclusive Licensing Agreement with Madrigal Pharmaceuticals
- Exclusive Licensing Agreement: Ribo Life Science has entered into a global exclusive licensing agreement with Madrigal Pharmaceuticals for six pre-clinical small interfering RNA (siRNA) programs targeting metabolic dysfunction-associated steatohepatitis (MASH), which is expected to drive the development of new therapies to meet increasing market demand.
- Financial Gains: Under the agreement, Ribo will receive an upfront payment of $60 million, with cumulative payments potentially reaching $4.4 billion upon achieving specific development, regulatory, and commercial milestones, highlighting the economic value and market potential of this collaboration.
- Technological Edge: The collaboration will leverage Ribo's GalSTARTM platform to develop bi-specific siRNAs, aiming to expand the therapeutic landscape for MASH through complementary multi-mechanistic approaches, thereby enhancing treatment efficacy and addressing unmet medical needs for patients.
- Market Demand: MASH is the leading cause of liver transplantation, and as disease awareness improves and prevalence rises, the number of patients with moderate to advanced fibrosis is expected to grow significantly, underscoring the urgency of developing effective treatment options.
See More
Ribo Enters Exclusive Licensing Agreement with Madrigal for siRNA Programs
- Exclusive Licensing Agreement: Suzhou Ribo Life Science has entered into a global exclusive licensing agreement with Madrigal Pharmaceuticals for six pre-clinical small interfering RNA (siRNA) programs targeting metabolic dysfunction-associated steatohepatitis (MASH), which is expected to drive the development of new therapies to meet growing market needs.
- Financial Gains: Under the agreement, Ribo will receive an upfront payment of $60 million, with cumulative payments potentially reaching $4.4 billion upon achieving specific development, regulatory, and commercial milestones, highlighting the economic value of this collaboration and its positive impact on Ribo's future financial outlook.
- Technological Platform Advantage: The collaboration will leverage Ribo's GalSTARTM platform to develop novel treatments for MASH, combining Madrigal's expertise in the field to provide more targeted and effective therapeutic options that address unmet patient needs.
- Broad Market Prospects: As awareness of MASH increases and prevalence rises, the number of patients with moderate to advanced fibrosis is expected to grow, further driving demand for new therapies and enhancing Ribo's competitive position in the biopharmaceutical market.
See More
Madrigal Pharmaceuticals Signs Exclusive Licensing Deal with Ribo Life Science
- Exclusive Licensing Agreement: Madrigal Pharmaceuticals has entered into an exclusive global licensing agreement with Suzhou Ribo Life Science and its subsidiary Ribocure Pharmaceuticals for six preclinical small interfering RNA (siRNA) programs targeting metabolic dysfunction-associated steatohepatitis (MASH), indicating the company's proactive approach in drug development.
- Financial Inflow: Under the deal, Ribo will receive $60 million upfront, with potential milestone payments reaching $4.4 billion, plus royalties on future sales, providing Madrigal with substantial funding to advance its research and development efforts.
- Technology Integration: Madrigal plans to combine siRNA technology with its drug Rezdiffra, which works by muting genes responsible for disease-driving proteins, potentially enhancing therapeutic efficacy and expanding market applications.
- Pipeline Expansion: Madrigal's pipeline also includes MGL-2086, with human studies scheduled later this year, further strengthening the company's competitive position and market presence in the treatment of metabolic diseases.
See More
Madrigal Pharmaceuticals Expands MASH Pipeline with New siRNA Programs
- Pipeline Expansion: Madrigal Pharmaceuticals has announced an exclusive global licensing agreement with Suzhou Ribo Life Science Co., acquiring six preclinical small interfering RNA (siRNA) programs, which is expected to enhance its leadership position in the metabolic dysfunction-associated steatohepatitis (MASH) space.
- Innovative Treatment Strategy: The company plans to develop next-generation siRNA therapies that target genes implicated in MASH, thereby precisely reducing the production of disease-driving proteins, which will provide more effective treatment options for patients with unmet medical needs.
- Clinical Research Progress: Currently, Madrigal's Rezdiffra is undergoing a fully enrolled F4c outcomes study, and its MASH pipeline has expanded to over 10 programs, including new drugs like MGL-2086 and Ervogastat, showcasing the company's robust R&D capabilities.
- Market Potential: With the increasing number of MASH patients, Madrigal's siRNA programs could potentially yield cumulative payments of up to $4.4 billion, indicating significant commercial potential in the rapidly growing MASH market.
See More
Madrigal Pharmaceuticals Enters $4.46B Licensing Deal with Suzhou Ribo
- Deal Value: Madrigal Pharmaceuticals has entered into an exclusive licensing agreement with Suzhou Ribo Life Science worth up to $4.46 billion, representing a significant advancement in the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
- Upfront Investment and Potential Earnings: Under the terms, Madrigal will pay Ribo $60 million upfront, with additional payments of up to $4.4 billion contingent on achieving development, regulatory, and commercial milestones, reflecting strong confidence in the collaboration.
- Technology Platform Utilization: Madrigal will leverage Ribo's liver-targeting small-interfering RNA (siRNA) GalSTAR platform to advance six preclinical programs aimed at developing new therapies for MASH, thereby enhancing treatment efficacy and addressing patient needs.
- Future Collaboration Expansion: The agreement includes provisions to expand the collaboration to new siRNA programs, such as bispecific siRNAs, indicating a long-term strategic partnership focused on innovative treatment solutions.
See More
Ribo Life Science Enters Exclusive Licensing Agreement with Madrigal Pharmaceuticals
- Exclusive Licensing Agreement: Ribo Life Science has entered into a global exclusive licensing agreement with Madrigal Pharmaceuticals for six pre-clinical small interfering RNA (siRNA) programs targeting metabolic dysfunction-associated steatohepatitis (MASH), which is expected to drive the development of new therapies to meet growing market demand.
- Financial Gains: Under the agreement, Ribo will receive an upfront payment of $60 million, with cumulative payments potentially reaching $4.4 billion upon achieving specific development, regulatory, and commercial milestones, highlighting the economic value and market potential of this collaboration.
- Technological Platform Advantage: The collaboration will leverage Ribo's GalSTARTM platform to develop bi-specific siRNAs, aiming to expand the therapeutic landscape for MASH through complementary multi-mechanistic approaches, thereby enhancing treatment efficacy and addressing unmet medical needs for patients.
- Growing Market Demand: As awareness of MASH disease increases and prevalence rises, the number of patients with moderate to advanced fibrosis is expected to grow, further driving the demand for new therapies and underscoring the significance of this collaboration.
See More
Ribo Life Science Enters Exclusive Licensing Agreement with Madrigal Pharmaceuticals
- Exclusive Licensing Agreement: Ribo Life Science has entered into a global exclusive licensing agreement with Madrigal Pharmaceuticals for six pre-clinical small interfering RNA (siRNA) programs targeting metabolic dysfunction-associated steatohepatitis (MASH), which is expected to drive the development of new therapies to meet increasing market demand.
- Financial Gains: Under the agreement, Ribo will receive an upfront payment of $60 million, with cumulative payments potentially reaching $4.4 billion upon achieving specific development, regulatory, and commercial milestones, highlighting the economic value and market potential of this collaboration.
- Technological Edge: The collaboration will leverage Ribo's GalSTARTM platform to develop bi-specific siRNAs, aiming to expand the therapeutic landscape for MASH through complementary multi-mechanistic approaches, thereby enhancing treatment efficacy and addressing unmet medical needs for patients.
- Market Demand: MASH is the leading cause of liver transplantation, and as disease awareness improves and prevalence rises, the number of patients with moderate to advanced fibrosis is expected to grow significantly, underscoring the urgency of developing effective treatment options.
See More
Ribo Enters Exclusive Licensing Agreement with Madrigal for siRNA Programs
- Exclusive Licensing Agreement: Suzhou Ribo Life Science has entered into a global exclusive licensing agreement with Madrigal Pharmaceuticals for six pre-clinical small interfering RNA (siRNA) programs targeting metabolic dysfunction-associated steatohepatitis (MASH), which is expected to drive the development of new therapies to meet growing market needs.
- Financial Gains: Under the agreement, Ribo will receive an upfront payment of $60 million, with cumulative payments potentially reaching $4.4 billion upon achieving specific development, regulatory, and commercial milestones, highlighting the economic value of this collaboration and its positive impact on Ribo's future financial outlook.
- Technological Platform Advantage: The collaboration will leverage Ribo's GalSTARTM platform to develop novel treatments for MASH, combining Madrigal's expertise in the field to provide more targeted and effective therapeutic options that address unmet patient needs.
- Broad Market Prospects: As awareness of MASH increases and prevalence rises, the number of patients with moderate to advanced fibrosis is expected to grow, further driving demand for new therapies and enhancing Ribo's competitive position in the biopharmaceutical market.
See More
Madrigal Pharmaceuticals Signs Exclusive Licensing Deal with Ribo Life Science
- Exclusive Licensing Agreement: Madrigal Pharmaceuticals has entered into an exclusive global licensing agreement with Suzhou Ribo Life Science and its subsidiary Ribocure Pharmaceuticals for six preclinical small interfering RNA (siRNA) programs targeting metabolic dysfunction-associated steatohepatitis (MASH), indicating the company's proactive approach in drug development.
- Financial Inflow: Under the deal, Ribo will receive $60 million upfront, with potential milestone payments reaching $4.4 billion, plus royalties on future sales, providing Madrigal with substantial funding to advance its research and development efforts.
- Technology Integration: Madrigal plans to combine siRNA technology with its drug Rezdiffra, which works by muting genes responsible for disease-driving proteins, potentially enhancing therapeutic efficacy and expanding market applications.
- Pipeline Expansion: Madrigal's pipeline also includes MGL-2086, with human studies scheduled later this year, further strengthening the company's competitive position and market presence in the treatment of metabolic diseases.
See More
